Presentations at the upcoming annual meeting will focus on AI-based analysis, biomarker prevalence, and therapy development.
NeoGenomics, Inc. will present eight scientific posters and one oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, California, from April 17 to 22.
The abstracts highlight how combining laboratory testing with clinical data can support oncology research, drive artificial intelligence (AI)-based analysis, and help translate findings into clinically relevant insights, according to the company. By linking testing results with real-world clinical data, NeoGenomics has demonstrated its capabilities to drive deeper characterization of biomarker prevalence, evaluation of testing concordance, and insights that help bridge translational research and clinical application.
“Bringing together lab and clinical data is becoming foundational to modern oncology research,” says Tony Zook, CEO at NeoGenomics, in a release. “Our collaborations with biopharma partners have allowed us to develop compelling research that we’re proud to present at AACR, showcasing how these insights can directly enhance therapy development and create optionality for providers and patients.”
Clinical Trial and Biomarker Research
The scheduled oral presentation, titled “Molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): The MERIDIAN Phase II trial,” will take place during the Clinical Trials Mini Symposium on April 20.
Additional research to be presented in poster sessions covers a range of oncology diagnostic solutions, including:
Biomarker Identification: Rapid identification of multi-omic protein and RNA biomarkers on a single formalin-fixed paraffin-embedded tissue section using a new integrated workflow.
Immuno-Oncology: An antibody-drug conjugate immuno-oncology panel for detailed characterization of the tumor and associated microenvironment.
AI Applications: Automated phenotyping of multiplex immunofluorescence datasets and AI-based detection and scoring of TROP2 expression in non-small cell lung cancer (NSCLC) specimens.
Hematologic Malignancies: The real-world landscape of KMT2A and NPM1 variants and fusions in hematologic malignancies, as well as the prognostic effect of the ferroptosis suppressor FSP1 in diffuse large B-cell lymphoma.
Tumor Microenvironment: Research on how metabolic reprogramming in advanced renal tumors contributes to a dysfunctional immune response and immune exhaustion.
Sarcoma Testing: Identification of molecular alterations in soft tissue sarcoma patients using combined pan-cancer genomic profiling and bespoke sarcoma fusion detection testing.
The company states that these integrated insights have the potential to enable oncology therapy development and commercialization.
ID 183384290 © Anawat Sudchanham | Dreamstime.com
